HARMONi-2 trial results comparing two treatments for PD-L1–positive non-small cell lung cancer: a plain language summary

This Plain Language Summary of Publication article (PLSP) from Future Oncology summarised HARMONi-2, which studied ivonescimab, a new cancer treatment, versus pembrolizumab (an approved therapy) as first-line treatment for Chinese patients with advanced PD-L1–positive non-small cell lung cancer. The study compared how well these two treatments worked for patients who had not received prior cancer therapy.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China’ and was published in The Lancet.

Visit The Lancet using the link to read the original article.

• clinical trial
• HARMONi-2
• Ivonescimab
• non-small cell lung cancer
• non-squamous
• PD-L1
• plain language summary
• Squamous